Compare · KNTE vs NVS
KNTE vs NVS
Side-by-side comparison of Kinnate Biopharma Inc. (KNTE) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KNTE and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $279.39B, about 620.8x KNTE ($450.1M).
- NVS has more recent analyst coverage (25 ratings vs 5 for KNTE).
- Company
- Kinnate Biopharma Inc.
- Novartis AG
- Price
- $2.65-0.38%
- $149.11+1.78%
- Market cap
- $450.1M
- $279.39B
- 1M return
- -
- +2.12%
- 1Y return
- -
- +26.33%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 25
Kinnate Biopharma Inc.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Diego, California.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest KNTE
- SEC Form 15-12G filed by Kinnate Biopharma Inc.
- Tananbaum James B. returned 13,718,311 shares to the company (SEC Form 4)
- Krishnamohan Neha returned 64,087 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Mitchell Dean J
- Farzan Nima returned 2,186 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Epperly Melissa B,
- SEC Form 4 filed by Smaldone Alsup Laurie
- Flaherty Keith T. returned 66,377 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Sabzevari Helen
- SEC Form 4 filed by Rome Michael E
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG